Inhaled Insulin Afrezza: How It Works and Who It Is For

What Is Afrezza?

Afrezza is the only FDA-approved inhaled insulin currently available in the United States. Developed by MannKind Corporation and approved in 2014, it offers people with diabetes a needle-free alternative for managing blood sugar spikes at mealtimes. Instead of an injection, Afrezza is delivered through a small, discreet inhaler that fits in the palm of your hand.

How Does Afrezza Work?

Afrezza contains technosphere insulin, a ultra-rapid-acting form of human insulin that is absorbed through the lungs directly into the bloodstream. Because it bypasses the subcutaneous tissue (the layer under the skin where injections are administered), it works significantly faster than most injectable rapid-acting insulins.

• Onset: Begins working within 12 to 15 minutes of inhalation
• Peak: Reaches peak activity at approximately 30 minutes
• Duration: Clears the body within 2 to 3 hours

This speed more closely mimics the body's natural insulin response to a meal, which can help reduce post-meal blood sugar spikes more effectively than some traditional injectable options. Resources like mdsdiabetes.com provide helpful comparisons of insulin types for those exploring their options.

Who Is Afrezza Approved For?

Afrezza is approved for use in adults with both Type 1 and Type 2 diabetes who need mealtime insulin coverage. It is taken just before eating and is typically used alongside a long-acting basal insulin to provide full 24-hour glucose management.

Afrezza may be particularly well-suited for:

• People who experience needle anxiety or injection phobia
• Individuals who struggle with post-meal blood sugar spikes
• Those who want a faster-acting mealtime insulin option
• People who find injections inconvenient in social or professional settings

Who Should NOT Use Afrezza?

Afrezza is not appropriate for everyone. The FDA has placed a boxed warning on the medication due to the risk of acute bronchospasm in people with chronic lung disease. The following individuals should avoid Afrezza:

• People with asthma or COPD — it is contraindicated for these groups
• Individuals who smoke or have recently quit smoking
• People with chronic lung infections or other significant pulmonary conditions
• Children and adolescents (safety not established in this age group)
• Pregnant women (injectable insulin is preferred during pregnancy)

Before starting Afrezza, a lung function test (spirometry) is required to confirm adequate pulmonary health.

Dosing and Administration

Afrezza comes in single-use cartridges of 4 units, 8 units, and 12 units. You insert a cartridge into the inhaler and inhale deeply at the start of a meal. Doses can be combined to achieve larger amounts as directed by your healthcare provider. Unlike injectable insulin that can be precisely titrated, Afrezza's fixed-dose cartridges may require some adjustment in dosing strategy.

Potential Side Effects

The most commonly reported side effects of Afrezza include:

• Cough (the most frequent complaint)
• Throat irritation or pain
• Hypoglycemia (low blood sugar)
• Decline in lung function with long-term use
• Headache

Is Afrezza Right for You?

Afrezza represents a meaningful innovation in diabetes management, especially for those who prefer to avoid needles or want faster mealtime coverage. However, it is not a universal solution. Always discuss your full medical history, breathing health, and lifestyle needs with your endocrinologist or diabetes care team before making a switch. Personalized guidance from certified diabetes educators can make all the difference in finding the right insulin regimen for your life.